Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.

Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai W, de la Cruz-Merino L, Bryan LJ, Houot R, Linton K, Briones J, Chau I, von Keudell GR, Lu H, Yakovich A, Chen M, Meulen Jh T, Yurasov S, Hsu FJ, Flowers CR

Open source

DOI: 10.1080/10428194.2021.2010057
Published: 2022 Apr
Container: Leukemia & lymphoma
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/10428194.2021.2010057,
  title = {Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.},
  author = {Halwani AS and Panizo C and Isufi I and Herrera AF and Okada CY and Cull EH and Kis B and Chaves JM and Bartlett NL and Ai W and de la Cruz-Merino L and Bryan LJ and Houot R and Linton K and Briones J and Chau I and von Keudell GR and Lu H and Yakovich A and Chen M and Meulen Jh T and Yurasov S and Hsu FJ and Flowers CR},
  year = {2022},
  journal = {Leukemia \& lymphoma},
  doi = {10.1080/10428194.2021.2010057},
  url = {https://doi.org/10.1080/10428194.2021.2010057}
}

RIS

TY  - JOUR
TI  - Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.
AU  - Halwani AS
AU  - Panizo C
AU  - Isufi I
AU  - Herrera AF
AU  - Okada CY
AU  - Cull EH
AU  - Kis B
AU  - Chaves JM
AU  - Bartlett NL
AU  - Ai W
AU  - de la Cruz-Merino L
AU  - Bryan LJ
AU  - Houot R
AU  - Linton K
AU  - Briones J
AU  - Chau I
AU  - von Keudell GR
AU  - Lu H
AU  - Yakovich A
AU  - Chen M
AU  - Meulen Jh T
AU  - Yurasov S
AU  - Hsu FJ
AU  - Flowers CR
PY  - 2022
JO  - Leukemia & lymphoma
DO  - 10.1080/10428194.2021.2010057
UR  - https://doi.org/10.1080/10428194.2021.2010057
ER  -

APA

AS, H., C, P., I, I., AF, H., CY, O., EH, C., B, K., JM, C., NL, B., W, A., L, D. L. C., LJ, B., R, H., K, L., J, B., I, C., GR, V. K., H, L., A, Y., M, C., T, M. J., S, Y., FJ, H., & CR, F. (2022). Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.. Leukemia & lymphoma. https://doi.org/10.1080/10428194.2021.2010057

Source records

pubmed · retrieved 2026-09-26T15:00:15.497Z